TMCI

Treace Medical Concepts Inc. (TMCI) | Rumor.io

Treace Medical Concepts

TMCI

Attention (50-day avg)0%

Attention rank (50-day avg)#4,171

Bullish sentiment (50-day avg)100%

Price to earnings ratio-4.81

Market capitalization291.4M

Earnings per share-0.92

Dividend yield (TTM)—

Revenue (annual)212.7M

Net income (annual)-59M

Social

What share of all stock conversation is about TMCI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 11

Treace Medical Concepts, Inc. (TMCI) CEO John T. Treace made a significant insider buy, purchasing 52,317 shares at $4.03 for a total of $210,968.
This purchase represents a 0.71% increase in the CEO's position and a 48% decrease in the stock's value from its 52-week high.
The insider buy is a strong signal, with Treace now owning 12,700,279 shares of TMCI.

Generated by AI

Sentiment

Of the messages about TMCI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	89.44% +1.83
Bearish	—	—	0%	10.56% -1.83

Bullish· Apr 10

Treace Medical Concepts, Inc. is experiencing a significant price increase of +26% and +30% due to its expanding product pipeline in bunion and midfoot surgery.
The company's recent rollout progress around Lapiplasty Lightning and the first surgical cases with the new SuperBite compression screw system are adding to its momentum.
The successful launch of the SuperBite Compression Screw System is expected to significantly enhance Treace Medical's surgical portfolio, with a potential 112.8% recovery window towards the $4.26 zone.

Bearish· May 9

The stock's Q1 earnings report missed estimates and issued weak FY24 guidance, triggering analyst downgrades from Morgan Stanley, Truist Securities, and JP Morgan.
The company's 2024 revenue guidance fell short of expectations, with analysts anticipating high notes but getting a muted melody instead.
The stock's price may continue to fall, potentially reaching levels as low as $2 or $1, considering its historical price of $34 three years ago.

Generated by AI

Topics

Of the messages about TMCI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	34.53%
Earnings	—	—	—	25.9%
Macro	—	—	—	13.67%
Analysts	—	—	—	15.83%
Technical Analysis	—	—	—	10.07%
Controversies	—	—	—	0%

May 18

Stifel Nicolaus initiated coverage on Treace Medical Concepts with a Buy rating and a price target of $35.
Morgan Stanley initiated coverage on Treace Medical Concepts with an Equal-Weight rating and a price target of $30.
JPMorgan Chase initiated coverage on Treace Medical Concepts with an Overweight rating and a price target of $37.

Generated by AI

Community

Of the messages about TMCI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	13.64%
Newcomers	—	—	0%	86.36%

Regulars· Mar 8

Treace Medical Concepts, Inc. (TMCI) has seen a significant increase in stock price, jumping 19% after a strong Q4 earnings beat.
The company has filed its 10-K form, reporting 2022 FY earnings, and has also filed SEC Form S-8 for a stock option plan.
TMCI's stock price has ripped 17% to $23.67, with EPS and revenue beating expectations, at $-0.08 and $49.77M, respectively.

Newcomers· May 8

New investors are buying Treace Medical Concepts, Inc. despite its recent 63% price drop, citing its strong revenue and lack of balance sheet issues.
A recent financial report and pre-market price drop have led some to believe that Treace Medical Concepts, Inc. may return to its 2021 IPO price, a significant loss.
A BTIG analyst has downgraded Treace Medical Concepts, Inc. from a Buy to a Neutral rating, which may have contributed to the company's recent decline.

Generated by AI

Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced five-year ALIGN3D results on September 17, adding longer-term evidence for the Lapiplasty bunion-correction procedure. The final analysis included 137 of 173 treated patients, or approximately 79% of the original group. Reported radiographic recurrence was 0.8% when defined as a hallux valgus angle greater than 20 degrees and 5.3% using […]

7d agoYahoo Finance

Treace Medical Looks Unlikely To Recover, A Founder-Led Broken Growth Story (NASDAQ:TMCI)

Treace Medical outlook: revenue declines, Lapiplasty losing share, margins compressing, and EBITDA delayed. Click for more on TMCI stock.

10d agoSeeking Alpha

Treace Medical presents 5-year bunion surgery study results

12d agoInvesting.com

Treace Medical (TMCI) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

Truist Financial Reaffirms Their Hold Rating on Treace Medical Concepts (TMCI)

Detailed price information for Treace Medical Concepts Inc (TMCI-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Truist Securities Adjusts PT on Treace Medical Concepts to $5 From $4, Keeps Hold Rating

Treace Medical Concepts (TMCI) has an average rating of hold and mean price target of $5.17, accordi

1mo agofinance.yahoo.com

Also Discussed

Investors talking about TMCI also mention

#	Name	Attention
1	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
2	Samfine Creation Holdings Group Ltd. Class A Ordinary SharesSFHG	0%new
3	Sonoma Pharmaceuticals Inc.SNOA	0%0
4	Presidio Property Trust, Inc. Class A Common StockSQFT	0%new
5	Dawson Geophysical Company Common StockDWSN	0%0
6	Huachen AI Parking Management Technology Holding Co., Ltd. Class A Ordinary SharesHCAI	0%new
7	Pulmonx CorporationLUNG	0%0
8	InnovAge Holding Corp.INNV	0%0
9	Sadot Group Inc.SDOT	0%new
10	Battalion Oil CorpBATL	0.03%+0.01

Treace Medical Concepts Inc.

Healthcare
Medical Devices

Treace Medical Concepts Inc. is a medical technology company focused on orthopedic solutions for foot and ankle care. Its core offerings include surgical systems, instruments, implants, and biologic solutions designed for the treatment of bunion deformities and related midfoot conditions. The company’s product portfolio is centered on procedures that help surgeons address the underlying structure of hallux valgus, with systems such as Lapiplasty supporting three-dimensional bunion correction. Treace Medical Concepts serves orthopedic surgeons, podiatrists, ambulatory surgery centers, and other healthcare providers involved in foot and ankle surgery. Its products are used in commercial-stage clinical settings and are part of the broader medical devices market, where the company contributes specialized tools intended to improve procedural consistency and surgical workflow. Headquartered in Ponte Vedra Beach, Florida, Treace Medical Concepts operates as a focused player in the musculoskeletal device segment, with an emphasis on dedicated treatment solutions for bunion and midfoot procedures.

Website

Location

100 Palmetto Park Place

Ponte Vedra, FL, 32081

United States

Social

What share of all stock conversation is about TMCI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 11

Treace Medical Concepts, Inc. (TMCI) CEO John T. Treace made a significant insider buy, purchasing 52,317 shares at $4.03 for a total of $210,968.
This purchase represents a 0.71% increase in the CEO's position and a 48% decrease in the stock's value from its 52-week high.
The insider buy is a strong signal, with Treace now owning 12,700,279 shares of TMCI.

Generated by AI

Sentiment

Of the messages about TMCI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	89.44% +1.83
Bearish	—	—	0%	10.56% -1.83

Bullish· Apr 10

Treace Medical Concepts, Inc. is experiencing a significant price increase of +26% and +30% due to its expanding product pipeline in bunion and midfoot surgery.
The company's recent rollout progress around Lapiplasty Lightning and the first surgical cases with the new SuperBite compression screw system are adding to its momentum.
The successful launch of the SuperBite Compression Screw System is expected to significantly enhance Treace Medical's surgical portfolio, with a potential 112.8% recovery window towards the $4.26 zone.

Bearish· May 9

The stock's Q1 earnings report missed estimates and issued weak FY24 guidance, triggering analyst downgrades from Morgan Stanley, Truist Securities, and JP Morgan.
The company's 2024 revenue guidance fell short of expectations, with analysts anticipating high notes but getting a muted melody instead.
The stock's price may continue to fall, potentially reaching levels as low as $2 or $1, considering its historical price of $34 three years ago.

Generated by AI

Topics

Of the messages about TMCI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	34.53%
Earnings	—	—	—	25.9%
Macro	—	—	—	13.67%
Analysts	—	—	—	15.83%
Technical Analysis	—	—	—	10.07%
Controversies	—	—	—	0%

May 18

Stifel Nicolaus initiated coverage on Treace Medical Concepts with a Buy rating and a price target of $35.
Morgan Stanley initiated coverage on Treace Medical Concepts with an Equal-Weight rating and a price target of $30.
JPMorgan Chase initiated coverage on Treace Medical Concepts with an Overweight rating and a price target of $37.

Generated by AI

Community

Of the messages about TMCI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	13.64%
Newcomers	—	—	0%	86.36%

Regulars· Mar 8

Treace Medical Concepts, Inc. (TMCI) has seen a significant increase in stock price, jumping 19% after a strong Q4 earnings beat.
The company has filed its 10-K form, reporting 2022 FY earnings, and has also filed SEC Form S-8 for a stock option plan.
TMCI's stock price has ripped 17% to $23.67, with EPS and revenue beating expectations, at $-0.08 and $49.77M, respectively.

Newcomers· May 8

New investors are buying Treace Medical Concepts, Inc. despite its recent 63% price drop, citing its strong revenue and lack of balance sheet issues.
A recent financial report and pre-market price drop have led some to believe that Treace Medical Concepts, Inc. may return to its 2021 IPO price, a significant loss.
A BTIG analyst has downgraded Treace Medical Concepts, Inc. from a Buy to a Neutral rating, which may have contributed to the company's recent decline.

Generated by AI

Treace Medical Concepts

Social

Jun 11

Sentiment

Bullish· Apr 10

Bearish· May 9

Topics

May 18

Community

Regulars· Mar 8

Newcomers· May 8

News

Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?

Treace Medical Looks Unlikely To Recover, A Founder-Led Broken Growth Story (NASDAQ:TMCI)

Treace Medical presents 5-year bunion surgery study results

Treace Medical (TMCI) Q2 2026 Earnings Call Transcript

Truist Financial Reaffirms Their Hold Rating on Treace Medical Concepts (TMCI)

Truist Securities Adjusts PT on Treace Medical Concepts to $5 From $4, Keeps Hold Rating

Also Discussed

Treace Medical Concepts Inc.

Company Information

Location

Social

Jun 11

Sentiment

Bullish· Apr 10

Bearish· May 9

Topics

May 18

Community

Regulars· Mar 8

Newcomers· May 8

News

Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?

Treace Medical Looks Unlikely To Recover, A Founder-Led Broken Growth Story (NASDAQ:TMCI)

Treace Medical presents 5-year bunion surgery study results

Treace Medical (TMCI) Q2 2026 Earnings Call Transcript

Truist Financial Reaffirms Their Hold Rating on Treace Medical Concepts (TMCI)

Truist Securities Adjusts PT on Treace Medical Concepts to $5 From $4, Keeps Hold Rating

Also Discussed